Kilitch Drugs (India) Limited (KILITCH.NS)
INR 317.15
(-1.14%)
INR 317.15
(-1.14%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 620.47 Million INR | -4.31% |
| 2022 | 648.4 Million INR | 32.87% |
| 2021 | 488 Million INR | 56.33% |
| 2020 | 312.15 Million INR | 28.81% |
| 2019 | 242.34 Million INR | -29.39% |
| 2018 | 343.21 Million INR | 37.21% |
| 2017 | 250.14 Million INR | 57.93% |
| 2016 | 158.38 Million INR | 45.31% |
| 2015 | 108.99 Million INR | -9.25% |
| 2014 | 120.11 Million INR | 53.84% |
| 2013 | 78.07 Million INR | 43.61% |
| 2012 | 54.36 Million INR | -84.94% |
| 2011 | 361.1 Million INR | 13.32% |
| 2010 | 318.65 Million INR | -0.99% |
| 2009 | 321.85 Million INR | 8.7% |
| 2008 | 296.1 Million INR | 6.05% |
| 2007 | 279.19 Million INR | 269.76% |
| 2006 | 75.5 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 113.6 Million INR | -32.23% |
| 2023 FY | 620.47 Million INR | -4.31% |
| 2023 Q2 | 209.96 Million INR | 7.42% |
| 2023 Q1 | 195.45 Million INR | -1.93% |
| 2023 Q3 | 148.05 Million INR | -29.49% |
| 2023 Q4 | 167.61 Million INR | 13.21% |
| 2022 FY | 648.4 Million INR | 32.87% |
| 2022 Q2 | 152.94 Million INR | 15.08% |
| 2022 Q3 | 163.24 Million INR | 6.74% |
| 2022 Q4 | 199.31 Million INR | 22.09% |
| 2022 Q1 | 132.9 Million INR | -17.59% |
| 2021 Q1 | 86.31 Million INR | 1.4% |
| 2021 Q2 | 106.09 Million INR | 22.91% |
| 2021 Q3 | 134.33 Million INR | 26.63% |
| 2021 Q4 | 161.26 Million INR | 20.04% |
| 2021 FY | 488 Million INR | 56.33% |
| 2020 Q3 | 101.89 Million INR | 6.76% |
| 2020 FY | 312.15 Million INR | 28.81% |
| 2020 Q2 | 95.44 Million INR | 221.5% |
| 2020 Q1 | 29.68 Million INR | -45.64% |
| 2020 Q4 | 85.12 Million INR | -16.46% |
| 2019 Q3 | 68.11 Million INR | -14.53% |
| 2019 Q2 | 79.69 Million INR | 99.59% |
| 2019 Q1 | 39.92 Million INR | -56.88% |
| 2019 Q4 | 54.6 Million INR | -19.83% |
| 2019 FY | 242.34 Million INR | -29.39% |
| 2018 Q3 | 38.24 Million INR | -62.79% |
| 2018 FY | 343.21 Million INR | 37.21% |
| 2018 Q4 | 92.59 Million INR | 142.12% |
| 2018 Q2 | 102.75 Million INR | -6.27% |
| 2018 Q1 | 109.62 Million INR | 0.0% |
| 2017 FY | 250.14 Million INR | 57.93% |
| 2016 FY | 158.38 Million INR | 45.31% |
| 2015 FY | 108.99 Million INR | -9.25% |
| 2014 Q3 | 19.96 Million INR | -55.8% |
| 2014 Q2 | 45.16 Million INR | 56.94% |
| 2014 Q1 | 28.77 Million INR | 685.02% |
| 2014 Q4 | 851 Thousand INR | -95.74% |
| 2014 FY | 120.11 Million INR | 53.84% |
| 2013 Q3 | 5.6 Million INR | -73.29% |
| 2013 Q2 | 20.99 Million INR | 19.92% |
| 2013 Q1 | 17.5 Million INR | 1337.03% |
| 2013 Q4 | 3.66 Million INR | -34.61% |
| 2013 FY | 78.07 Million INR | 43.61% |
| 2012 Q3 | 16.35 Million INR | 83.59% |
| 2012 Q2 | 8.91 Million INR | -64.95% |
| 2012 FY | 54.36 Million INR | -84.94% |
| 2012 Q1 | 25.42 Million INR | 0.0% |
| 2012 Q4 | 1.21 Million INR | -92.55% |
| 2011 FY | 361.1 Million INR | 13.32% |
| 2010 FY | 318.65 Million INR | -0.99% |
| 2009 FY | 321.85 Million INR | 8.7% |
| 2008 FY | 296.1 Million INR | 6.05% |
| 2007 FY | 279.19 Million INR | 269.76% |
| 2006 FY | 75.5 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Sigachi Industries Limited | 2 Billion INR | 69.012% |
| Ind-Swift Limited | 2.17 Billion INR | 71.44% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 57.842% |
| Sakar Healthcare Limited | 699.58 Million INR | 11.308% |
| Aurobindo Pharma Limited | 109.54 Billion INR | 99.434% |
| Innova Captab Limited | 3.46 Billion INR | 82.09% |
| Divi's Laboratories Limited | 32.44 Billion INR | 98.087% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 90.029% |
| Morepen Laboratories Limited | 6.16 Billion INR | 89.929% |
| Mankind Pharma Limited | 42.19 Billion INR | 98.53% |
| Sequent Scientific Limited | 2.97 Billion INR | 79.17% |
| Wanbury Limited | 1.73 Billion INR | 64.148% |
| Laurus Labs Limited | 15.44 Billion INR | 95.984% |
| Nectar Lifesciences Limited | 4.82 Billion INR | 87.136% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 95.009% |
| Alembic Limited | 1 Billion INR | 37.959% |
| Hikal Limited | 5.95 Billion INR | 89.586% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 97.683% |
| Neuland Laboratories Limited | 8.24 Billion INR | 92.477% |
| J. B. Chemicals & Pharmaceuticals Limited | 15.25 Billion INR | 95.934% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 99.105% |
| IOL Chemicals and Pharmaceuticals Limited | 4.71 Billion INR | 86.852% |
| Themis Medicare Limited | 2.42 Billion INR | 74.361% |
| RPG Life Sciences Limited | 2.48 Billion INR | 75.011% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.504% |
| Lupin Limited | 125.09 Billion INR | 99.504% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | 70.369% |
| Wockhardt Limited | 7.72 Billion INR | 91.963% |
| Vaishali Pharma Limited | 90.32 Million INR | -586.953% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 89.36% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | 4.921% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 96.841% |
| FDC Limited | 6.58 Billion INR | 90.579% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.621% |
| Eris Lifesciences Limited | 10.42 Billion INR | 94.049% |
| Venus Remedies Limited | 2.18 Billion INR | 71.571% |
| ZIM Laboratories Limited | 1.26 Billion INR | 51.059% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 83.21% |
| Par Drugs and Chemicals Limited | 529.13 Million INR | -17.262% |
| Caplin Point Laboratories Limited | 9.2 Billion INR | 93.26% |
| Shilpa Medicare Limited | 3.56 Billion INR | 82.58% |
| Albert David Limited | 1.4 Billion INR | 55.935% |
| Ajanta Pharma Limited | 21.06 Billion INR | 97.054% |
| Hester Biosciences Limited | 1.27 Billion INR | 51.284% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 84.952% |
| Solara Active Pharma Sciences Limited | -1.65 Billion INR | 137.471% |
| Gufic Biosciences Limited | 4.07 Billion INR | 84.769% |
| Windlas Biotech Limited | 1.33 Billion INR | 53.654% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 89.268% |
| Aarey Drugs & Pharmaceuticals Limited | 113.02 Million INR | -448.954% |
| Mangalam Drugs & Organics Limited | 691.19 Million INR | 10.231% |
| Granules India Limited | 16.79 Billion INR | 96.307% |
| Aarti Drugs Limited | 8.31 Billion INR | 92.539% |
| Bal Pharma Limited | 770.19 Million INR | 19.439% |
| Alkem Laboratories Limited | 52.29 Billion INR | 98.814% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.76% |
| Lincoln Pharmaceuticals Limited | 1.88 Billion INR | 67.116% |
| Medicamen Biotech Limited | 495.49 Million INR | -25.224% |
| Unichem Laboratories Limited | 4.86 Billion INR | 87.246% |
| Bafna Pharmaceuticals Limited | 452.15 Million INR | -37.227% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.54 Million INR | -4846.01% |
| Valiant Laboratories Limited | 138.02 Million INR | -349.527% |
| Orchid Pharma Limited | 2.32 Billion INR | 73.259% |
| Medico Remedies Limited | 262.14 Million INR | -136.693% |
| Ind-Swift Laboratories Limited | 4.13 Billion INR | 84.988% |
| Ipca Laboratories Limited | 48.58 Billion INR | 98.723% |
| Brooks Laboratories Limited | 65.62 Million INR | -845.561% |
| Syncom Formulations (India) Limited | 559.5 Million INR | -10.898% |
| Piramal Enterprises Limited | 8.04 Billion INR | 92.286% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 98.673% |
| NATCO Pharma Limited | 25.73 Billion INR | 97.589% |
| Suven Life Sciences Limited | -200.79 Million INR | 409.007% |
| Krebs Biochemicals & Industries Limited | -108.74 Million INR | 670.569% |
| Strides Pharma Science Limited | 14.38 Billion INR | 95.688% |
| Indoco Remedies Limited | 8.04 Billion INR | 92.286% |
| Alpa Laboratories Limited | 188.89 Million INR | -228.477% |
| Lasa Supergenerics Limited | 121.02 Million INR | -412.664% |
| Sun Pharma Advanced Research Company Limited | 391.06 Million INR | -58.663% |